Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma

IMPORTANCE: Immune checkpoint inhibitors have been approved for use as a second-line therapy for hepatocellular carcinoma (HCC) in patients who previously received sorafenib. Pembrolizumab has shown substantial antitumor activity and a favorable toxicity profile as a second-line treatment of HCC. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiang, Chi-leung, Chan, Sik-kwan, Lee, Shing-fung, Wong, Irene Oi-ling, Choi, Horace Cheuk-wai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816108/
https://www.ncbi.nlm.nih.gov/pubmed/33464318
http://dx.doi.org/10.1001/jamanetworkopen.2020.33761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816108/
https://www.ncbi.nlm.nih.gov/pubmed/33464318
http://dx.doi.org/10.1001/jamanetworkopen.2020.33761

Ejemplares similares